These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30580044)

  • 1. Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology.
    Christophe B; Crumb WJ
    J Pharmacol Toxicol Methods; 2019; 96():15-26. PubMed ID: 30580044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: In silico study using 109 torsadogenic or non-torsadogenic compounds.
    Christophe B
    Toxicol Appl Pharmacol; 2022 Mar; 438():115914. PubMed ID: 35150662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
    Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
    J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of early after-depolarisation in non-failing human ventricular myocytes: can this help cardiac safety pharmacology?
    Christophe B
    Pharmacol Rep; 2013; 65(5):1281-93. PubMed ID: 24399724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
    Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
    J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
    Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
    Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
    Cavero I; Holzgrefe H
    Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CiPA: Ongoing testing, future qualification procedures, and pending issues.
    Cavero I; Holzgrefe H
    J Pharmacol Toxicol Methods; 2015; 76():27-37. PubMed ID: 26159293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Llopis-Lorente J; Gomis-Tena J; Cano J; Romero L; Saiz J; Trenor B
    J Chem Inf Model; 2020 Oct; 60(10):5172-5187. PubMed ID: 32786710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.
    Ando H; Yoshinaga T; Yamamoto W; Asakura K; Uda T; Taniguchi T; Ojima A; Shinkyo R; Kikuchi K; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
    J Pharmacol Toxicol Methods; 2017; 84():111-127. PubMed ID: 27956204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of an
    Dutta S; Chang KC; Beattie KA; Sheng J; Tran PN; Wu WW; Wu M; Strauss DG; Colatsky T; Li Z
    Front Physiol; 2017; 8():616. PubMed ID: 28878692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
    Kanda Y; Yamazaki D; Osada T; Yoshinaga T; Sawada K
    J Pharmacol Sci; 2018 Dec; 138(4):233-239. PubMed ID: 30415824
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Boulay E; Troncy E; Jacquemet V; Huang H; Pugsley MK; Downey AM; Venegas Baca R; Authier S
    Int J Toxicol; 2024; 43(4):357-367. PubMed ID: 38477622
    [No Abstract]   [Full Text] [Related]  

  • 15. Ventricular rate adaptation: a novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds.
    Green JR; Diaz GJ; Limberis JT; Houseman KA; Su Z; Martin RL; Cox BF; Kantor S; Gintant GA
    J Pharmacol Toxicol Methods; 2011; 64(1):68-73. PubMed ID: 21440075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure.
    Leishman DJ
    J Pharmacol Toxicol Methods; 2020; 101():106654. PubMed ID: 31730936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
    Vicente J; Stockbridge N; Strauss DG
    J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
    Wallis R; Benson C; Darpo B; Gintant G; Kanda Y; Prasad K; Strauss DG; Valentin JP
    J Pharmacol Toxicol Methods; 2018; 93():15-25. PubMed ID: 29958940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considering population variability of electrophysiological models improves the in silico assessment of drug-induced torsadogenic risk.
    Llopis-Lorente J; Trenor B; Saiz J
    Comput Methods Programs Biomed; 2022 Jun; 221():106934. PubMed ID: 35687995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
    J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.